期刊文献+

激素联合环磷酰胺治疗间质性肺疾病及对患者血清白介-6水平的影响 被引量:4

Hormone Combined with Cyclophosphamide in Treatment of Interstitial Lung Disease and Its Effect on Serum Interleukin-6 in Patients
下载PDF
导出
摘要 目的探讨激素联合环磷酰胺治疗间质性肺疾病对患者血清白介-6水平的影响。方法选取该院2014年3月—2015年7月间收治的120例间质性肺疾病患者随机分组,观察组60例给予激素联合环磷酰胺治疗,对照组60例单纯给予激素治疗,比较两组患者治疗前后FEV1、FVC、FVC(%)、DLCO、DLCO(%)、HRCT评分、IL-6水平。结果两组患者治疗前FEV1、FVC、FVC(%)、DLCO、DLCO(%)、HRCT评分、IL-6水平比较差异无统计学意义(P>0.05);观察组治疗后FEV1、FVC、FVC(%)、DLCO、DLCO(%)、HRCT评分、IL-6水平与对照组比较差异有统计学意义(P<0.05)。结论激素联合环磷酰胺治疗间质性肺疾病效果显著,能降低患者血清白介-6水平,缓解患者临床症状。 Objective To discuss the hormone combined with cyclophosphamide in treatment of interstitial lung disease and its effect on serum interleukin-6 in patients. Methods 120 cases of patients with interstitial lung disease treated in our hospital from March 2014 to July 2015 were randomly divided into two groups with 60 cases in each, the observation group were treated with hormone combined with cyclophosphamide, the control group were treated with simple hormone, and the FEV1, FVC, FVC(%), DLCO, DLCO(%), HRCT scores and IL-6 levels before and after treatment were compared between the two groups. Results There was no obvious difference in the FEV1, FVC, FVC(%), DLCO, DLCO(%), HRCT score and IL-6 level between the two groups before treatment(P〉0.05), there were obvious differences in the FEV1, FVC, FVC(%),DLCO, DLCO(%), HRCT score and IL-6 level between the two groups after treatment(P〈0.05). Conclusion The effect of hormone combined with cyclophosphamide in treatment of interstitial lung disease is obvious, which can reduce the serum interleukin-6 level and relieve the clinical symptoms of patients.
出处 《中外医疗》 2016年第12期50-51,共2页 China & Foreign Medical Treatment
关键词 激素 环磷酰胺 间质性肺疾病 血清白介-6 Hormone Cyclophosphamide Interstitial lung disease Serum interleukin-6
  • 相关文献

参考文献8

二级参考文献60

  • 1宋淑菊,段婷.以肺间质纤维化为首发表现的皮肌炎合并骨梗死1例[J].中国实用内科杂志,2006,26(3):390-391. 被引量:3
  • 2段报喜,黄润月,储永良.细胞因子治疗特发性肺纤维化[J].中国组织工程研究与临床康复,2007,11(10):1940-1942. 被引量:9
  • 3Beretta L, Caronni M, Raimondi M, et al. Oral cyclophosphamide improves pulmonary function in ~clerodenna patients with fibrosing alveolitis: experience in one centre [ J ]. Clin Rheumatol, 2007,26 (2) :168-172.
  • 4Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease [ J ]. N Engl J Med, 2006,354(25) :2655-2666.
  • 5Warrick JH, Bhalla M, Schabel SI, et al. High resolution computed tomography in early scleroderma lung disease [ J ]. J Rheumatol, 1991,18(10) :1520-1528.
  • 6Jones PW, Quirk FH, Baveystock CM, et al. The St George's Re- spiratory Questionnaire[J]. Respir Med, 1991,85 ( Suppl B) :25- 31.
  • 7Ware JE Jr, Sherboume CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection [ J ]. Med Care, 1992,30(6) :473-483.
  • 8ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test[J]. Am J Respir Crit Care Med, 2002,166 ( 1 ) : 111- 117.
  • 9Kim EA, Johkoh T, Lee KS, et al. Interstitial pneumonia in pro- gressive systemic sclerosis: serial high-resolution CT findings with functional correlation[J]. J Comput Assist Tomogr, 2001,25 (5) : 757-763.
  • 10Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant in- terstitial lung disease in limited scleroderma: histopathology, clini- cal features, and survival[ J]. Chest, 2008,134 (3) :601-605.

共引文献53

同被引文献15

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部